Preparation of stable and monodisperse paclitaxel-loaded bovine serum albumin nanoparticles via intermolecular disulfide crosslinking

Abstract

Paclitaxel (PTX) is one of the most used anti-cancer drugs worldwide. Due to its insolubility in water, the clinically available liquid formulation of PTX contains Cremophor EL that is responsible for severe hypersensitivity. Albumin-based nanoparticles have emerged as a promising carrier for anti-cancer drugs because albumin nanoparticles have high capacity to not only load lipophilic drugs without solubilizer but also accumulate in tumor by both passive and active mechanisms. In this study, we attempted to prepare solvent-free formulation of PTX-loaded bovine serum albumin (BSA) nanoparticles with high stability, and the in vitro stability in serum were comparatively assessed between our PTX-loaded BSA nanoparticles and clinically used nanoparticulate albumin-bound PTX (Abraxane®). PTX-loaded BSA nanoparticles were prepared by intermolecular disulfide crosslinking. When BSA molecules were used without denaturation by guanidinium, the obtained BSA nanoparticles showed broad size distribution. On the other hand, the nanoparticles composed of denatured BSA by guanidinium had a uniform size around 100 nm. The PTX encapsulation efficiency of BSA nanoparticles were approximately 30–40 %. In addition, in vitro gel filtration analysis and dialysis study demonstrated that PTX-loaded BSA nanoparticles had higher colloidal stability and sustained PTX release property than Abraxane® in serum. These results suggest that BSA nanoparticles is a promising drug carrier for improving therapeutic efficacy of PTX and reducing its adverse effects.

Keywords

• Albumin nanoparticle
• Paclitaxel
• Disulfide crosslinking
• Colloidal stability